• Contact Us
TriSalus Life Sciences
  • Our Story
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Boards
  • Our Passion
  • Our Approach
    • Multi-Pronged Approach
    • Immunomodulation
      • Toll-Like Receptor 9 Agonist
    • Drug Delivery
    • Our Products
  • Our Therapeutic Pipeline
    • Pipeline Overview
    • Product Candidates
      • SD-101
    • Clinical Trials for Healthcare Professionals
    • Scientific Publications & Presentations
  • Patients & Caregivers
    • Patients
    • Our Team Approach
    • Clinical Trials for Patients
    • Patient Resources
  • News & Events
    • News
    • Events
Select Page
TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

by Lisa DeScenza | Oct 22, 2020 | Home News (Right), News, News-2020

News & Events News TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer Experienced commercial leader solidifies Company’s management team as it integrates novel therapies with innovative drug delivery DENVER and CHICAGO, October 22, 2020 –...
TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

TriSalus Life Sciences Appoints Steven Katz, M.D., Chief Medical Officer

by Lisa DeScenza | Sep 29, 2020 | News, News-2020

News & Events News TriSalus Life Sciences Appoints Steven Katz, M.D., Chief Medical Officer Renowned surgeon, clinician, and researcher to advance work to combine novel immuno-oncology therapies with regional drug delivery to improve outcomes in metastatic liver...
TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate

by Lisa DeScenza | Sep 22, 2020 | News, News-2020

News & Events News TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate Initiating clinical trials to evaluate investigational toll-like receptor 9 agonist, SD-101, in patients with uveal melanoma liver metastases...
TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales

by Michael Persons | Aug 3, 2020 | News, News-2020

News & Events News TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9...
TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

TriSalus Appoints Rajesh B. Mistry Chief Financial Officer

by Michael Persons | Jun 1, 2020 | News, News-2020

News & Events News TriSalus Appoints Rajesh B. Mistry Chief Financial Officer June 1, 2020–TriSalus Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the appointment of Rajesh B. Mistry as Chief...
TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

TriSalus Life Sciences Launches the New TriNav™ Infusion System, an Innovative Solution Designed to Overcome Infusion Barriers Within Solid Tumors

by Michael Persons | Jan 13, 2020 | News, News-2020

News & Events News TriSalus Life Sciences Launches the New TriNav™ Infusion System, an Innovative Solution Designed to Overcome Infusion Barriers Within Solid Tumors January 13, 2020–TriSalus™ Life Sciences (“TriSalus”), a company committed to transforming...

Recent Posts

  • TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors
  • TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting
  • TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting
  • TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
  • PERIO-01: Enabling tumor microenvironment reprogramming by a TLR9 agonist using Pressure-Enabled Drug Delivery™ (PEDD™) to address intrahepatic immunosuppression and drug delivery barriers

Recent Comments

    Our Story Our Passion Our Approach Our Therapeutic Pipeline Patients & Caregivers News Events

    TriSalus Life Sciences
    6272 W. 91st Avenue
    Westminster, CO 80031

       

    © 2021 TriSalus™    All Rights Reserved   Privacy Policy   Compliance    Terms of Use

    You are now leaving the TriSalus Life Sciences corporate website.

    We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus' standards.

    Third Party Sites
    TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of TriSalus or this website.

    Thank you for visiting our site.